Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea

International Journal of Neuropsychopharmacology

Volumn 11, Issue 2, 2008, Pages 261-267

  Tanaka, Misuzu ^a   Kobayashi, Daisuke ^a   Murakami, Yuko ^a   Ozaki, Norio ^b   Suzuki, Tatsuyo ^c   Iwata, Nakao ^c   Haraguchi, Koichi ^d   Ieiri, Ichiro ^a   Kinukawa, Naoko ^a   Hosoi, Masako ^a   Ohtani, Hisakazu ^e   Sawada, Yasufumi ^e   Mine, Kazunori ^f  

^a KYUSHU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

Author keywords

5 hydroxytryptamine type 3B receptor; Genetic polymorphism; Nausea; Paroxetine; Selective serotonin reuptake inhibitor

Indexed keywords

CYTOCHROME P450 2D6; PAROXETINE; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN 3B RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; DEPRESSIVE DISORDER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NAUSEA; PAROXETINE; POLYMORPHISM, GENETIC; RECEPTORS, SEROTONIN, 5-HT3; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 38949107641     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007985     Document Type: Article

References (26)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
2. 3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. Journal of Psychopharmacology 9, 137-141.
3. 3 receptors. Proceedings of the National Academy of Sciences USA 102, 12595-12600.
4. Bergeron R, Blier P (1994). Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. American Journal of Psychiatry 151, 1084-1086.
5. Choi JS, Choi BH, Ahn HS, Kim MJ, Rhie DJ, Yoon SH, Min DS, Jo YH, Kim MS, Sung KW, Hahn SJ (2003). Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cells. Biochemical Pharmacology 66, 2125-2132.
6. 3B subunit is a major determinant of serotonin-receptor function. Nature 397, 359-363.
7. Dubin AE, Huvar R, D'Andrea MR, Pyati J, Zhu JY, Joy KC, Wilson SJ, Galindo JE, Glass CA, Luo L, et al. (1999). The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. Journal of Biological Chemistry 274, 30799-30810.
8. Eap CB, Bouchoux G, Amey M, Cochard N, Savary L, Baumann P (1998). Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. Journal of Chromatographic Science 36, 365-371.
9. Fan P (1994). Inhibition of a 5-HT3 receptor-mediated current by the selective serotonin uptake inhibitor, fluoxetine. Neuroscience Letters 173, 210-212.
10. Frank B, Niesler B, Nothen MM, Neidt H, Propping P, Bondy B, Rietschel M, Maier W, Albus M, Rappold G (2004). Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 131, 1-5.
11. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Journal of Clinical Oncology 24, 2932-2947.
12. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica (Suppl.) 334, 1-100.
13. Miller AD, Leslie RA (1994). The area postrema and vomiting. The area postrema and vomiting. Frontiers in Neuroendocrinology 15, 301-320.
14. Murphy Jr. GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF (2004). Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of General Psychiatry 61, 1163-1169.
15. Murphy Jr. GM, Kremer C, Rodrigues HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. American Journal of Psychiatry 160, 1830-1835.
16. Ottevanger EA (1994). SSRI treatment-emergent nausea. Neuropsychopharmacology 10 (Suppl. 3), 104S.
17. 2A receptor: similar prevalence in patients with seasonal affective disorder and controls. Biological Psychiatry 40, 1267-1272.
18. Sindrup SH, Brosen K, Gram LF (1992). Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clinical Pharmacology and Therapeutics 51, 288-295.
19. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T (2006). The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics Journal 6, 351-356.
20. Suzuki Y, Sawamura K, Someya T (2006). Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 31, 825-831.
21. Takahashi H, Yoshida K, Ito K, Sato K, Kamata M, Higuchi H, Shimizu T, Ito K, Inoue K, Tezuka T, et al. (2002). No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. European Neuropsychopharmacology 12, 477-481.
22. Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, Roots I, Brockmoller J (2003). Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. Journal of Clinical Oncology 21, 2147-2155.
23. 3 receptor antagonists. Oncology 49, 263-268.
24. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H (1992). Review of fluvoxamine safety database. Drugs 43 (Suppl. 2), 48-54.
25. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL (2002). Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 62, 655-703.
26. Zanger UM, Raimundo S, Eichelbaum M (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Archives of Pharmacology 369, 23-37.